318 related articles for article (PubMed ID: 29413958)
1. Multifaceted remodeling by vitamin C boosts sensitivity of Mycobacterium tuberculosis subpopulations to combination treatment by anti-tubercular drugs.
Sikri K; Duggal P; Kumar C; Batra SD; Vashist A; Bhaskar A; Tripathi K; Sethi T; Singh A; Tyagi JS
Redox Biol; 2018 May; 15():452-466. PubMed ID: 29413958
[TBL] [Abstract][Full Text] [Related]
2. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
[TBL] [Abstract][Full Text] [Related]
4. The pleiotropic transcriptional response of Mycobacterium tuberculosis to vitamin C is robust and overlaps with the bacterial response to multiple intracellular stresses.
Sikri K; Batra SD; Nandi M; Kumari P; Taneja NK; Tyagi JS
Microbiology (Reading); 2015 Apr; 161(Pt 4):739-53. PubMed ID: 25645949
[TBL] [Abstract][Full Text] [Related]
5. Mycobacterium tuberculosis transcriptional adaptation, growth arrest and dormancy phenotype development is triggered by vitamin C.
Taneja NK; Dhingra S; Mittal A; Naresh M; Tyagi JS
PLoS One; 2010 May; 5(5):e10860. PubMed ID: 20523728
[TBL] [Abstract][Full Text] [Related]
6. Novel Assay Platform to Evaluate Intracellular Killing of
Horváti K; Fodor K; Pályi B; Henczkó J; Balka G; Gyulai G; Kiss É; Biri-Kovács B; Senoner Z; Bősze S
Front Immunol; 2021; 12():750496. PubMed ID: 34867981
[TBL] [Abstract][Full Text] [Related]
7. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen.
Deb C; Lee CM; Dubey VS; Daniel J; Abomoelak B; Sirakova TD; Pawar S; Rogers L; Kolattukudy PE
PLoS One; 2009 Jun; 4(6):e6077. PubMed ID: 19562030
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs.
Subbian S; Tsenova L; O'Brien P; Yang G; Koo MS; Peixoto B; Fallows D; Dartois V; Muller G; Kaplan G
PLoS Pathog; 2011 Sep; 7(9):e1002262. PubMed ID: 21949656
[TBL] [Abstract][Full Text] [Related]
10. Multiple transcription factors co-regulate the Mycobacterium tuberculosis adaptation response to vitamin C.
Nandi M; Sikri K; Chaudhary N; Mande SC; Sharma RD; Tyagi JS
BMC Genomics; 2019 Nov; 20(1):887. PubMed ID: 31752669
[TBL] [Abstract][Full Text] [Related]
11. TB drug development: immunology at the table.
Nathan C; Barry CE
Immunol Rev; 2015 Mar; 264(1):308-18. PubMed ID: 25703568
[TBL] [Abstract][Full Text] [Related]
12. Drug targets in dormant Mycobacterium tuberculosis: can the conquest against tuberculosis become a reality?
Gupta VK; Kumar MM; Singh D; Bisht D; Sharma S
Infect Dis (Lond); 2018 Feb; 50(2):81-94. PubMed ID: 28933243
[TBL] [Abstract][Full Text] [Related]
13. Targeting redox heterogeneity to counteract drug tolerance in replicating
Mishra R; Kohli S; Malhotra N; Bandyopadhyay P; Mehta M; Munshi M; Adiga V; Ahuja VK; Shandil RK; Rajmani RS; Seshasayee ASN; Singh A
Sci Transl Med; 2019 Nov; 11(518):. PubMed ID: 31723039
[TBL] [Abstract][Full Text] [Related]
14. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice.
Vilchèze C; Kim J; Jacobs WR
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29298757
[TBL] [Abstract][Full Text] [Related]
15. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
16. Delamanid Kills Dormant Mycobacteria
Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
[TBL] [Abstract][Full Text] [Related]
17. Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis.
Ma S; Jaipalli S; Larkins-Ford J; Lohmiller J; Aldridge BB; Sherman DR; Chandrasekaran S
mBio; 2019 Nov; 10(6):. PubMed ID: 31719182
[TBL] [Abstract][Full Text] [Related]
18. Replication rates of Mycobacterium tuberculosis in human macrophages do not correlate with mycobacterial antibiotic susceptibility.
Raffetseder J; Pienaar E; Blomgran R; Eklund D; Patcha Brodin V; Andersson H; Welin A; Lerm M
PLoS One; 2014; 9(11):e112426. PubMed ID: 25386849
[TBL] [Abstract][Full Text] [Related]
19. The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis - insights for early bactericidal activity?
Pullan ST; Allnutt JC; Devine R; Hatch KA; Jeeves RE; Hendon-Dunn CL; Marsh PD; Bacon J
BMC Infect Dis; 2016 May; 16():205. PubMed ID: 27184366
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis.
Karakousis PC; Williams EP; Bishai WR
J Antimicrob Chemother; 2008 Feb; 61(2):323-31. PubMed ID: 18156607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
